Welcome to our dedicated page for Innate Pharma news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma stock.
Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Innate Pharma has secured €6.8M funding under the PSPC-COVID initiative to advance its COVID-19 research efforts. This funding from Bpifrance, a French government investment bank, aims to support R&D, including Phase II clinical trials initiated in March 2020. The funding will be disbursed in four tranches, with the first being €1.7M. The Company is focusing on its COVID-19 programs, such as the FORCE trial, which targets severe pneumonia in COVID-19 patients, and the ImmunONCOVID-20 study, which explores treatments for cancer patients with COVID-19 symptoms.